TEST BANK
LPharmacotherapeutics for Advanced Practice
A Practical Approach
Virginia Poole Arcangelo, Andrew M. Peterson, Veronica Wilbur,Tep M. Kang
5th Edition
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007614
lOM oA R c PS D| 21 007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007614
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The spoint sin stime son sthe sdrug sconcentration scurve sthat sindicates sthe sfirst ssign sof sa
stherapeutic seffect sis sthe:
A. Minimum sadverse seffect slevel
B. Peak sof saction
C. Onset sof saction
D. Therapeutic srange
ANS: s C PTS: s 1
8. Phenytoin srequires sa strough slevel sbe sdrawn. sPeak sand strough slevels sare sdone:
A. When sthe sdrug shas sa swide stherapeutic srange
B. When sthe sdrug swill sbe sadministered sfor sa sshort stime sonly
C. When sthere sis sa shigh scorrelation sbetween sthe sdose sand ssaturation sof sreceptor ssites
D. To sdetermine sif sa sdrug sis sin sthe stherapeutic srange
ANS: s D PTS: s 1
9. A slaboratory sresult sindicates sthe speak slevel sfor sa sdrug sis sabove sthe sminimum
stoxic sconcentration. sThis smeans sthat sthe:
A. Concentration swill sproduce stherapeutic seffects
B. Concentration swill sproduce san sadverse sresponse
C. Time sbetween sdoses smust sbe sshortened
D. Duration sof saction sof sthe sdrug sis stoo slong
ANS: s B PTS: s 1
10. Drugs sthat sare sreceptor sagonists smay sdemonstrate swhat sproperty?
A. Irreversible sbinding sto sthe sdrug sreceptor ssite
B. Up-regulation swith schronic suse
C. Desensitization sor sdown-regulation swith scontinuous suse
D. Inverse srelationship sbetween sdrug sconcentration sand sdrug saction
ANS: s C PTS: s 1
11. Drugs sthat sare sreceptor santagonists, ssuch sas sbeta sblockers, smay scause:
A. Down-regulation sof sthe sdrug sreceptor
B. An sexaggerated sresponse sif sabruptly sdiscontinued
C. Partial sblockade sof sthe seffects sof sagonist sdrugs
D. An sexaggerated sresponse sto scompetitive sdrug sagonists
ANS: s B PTS: s 1
12. Factors sthat saffect sgastric sdrug sabsorption sinclude:
A. Liver senzyme sactivity
B. Protein-binding sproperties sof sthe sdrug smolecule
C. Lipid ssolubility sof sthe sdrug
D. Ability sto schew sand sswallow
ANS: s C PTS: s 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
13. Drugs sadministered svia sintravenous s(IV) sroute:
A. Need sto sbe slipid ssoluble sin sorder sto sbe seasily sabsorbed
B. Begin sdistribution sinto sthe sbody simmediately
C. Are seasily sabsorbed sif sthey sare snonionized
D. May suse spinocytosis sto sbe sabsorbed
ANS: s B PTS: s 1
14. When sa smedication sis sadded sto sa sregimen sfor sa ssynergistic seffect, sthe scombined seffect
sof sthe sdrugs sis:
A. The ssum sof sthe seffects sof seach sdrug sindividually
B. Greater sthan sthe ssum sof sthe seffects sof seach sdrug sindividually
C. Less sthan sthe seffect sof seach sdrug sindividually
D. Not spredictable, sas sit svaries swith seach sindividual
ANS: s B PTS: s 1
15. Which sof sthe sfollowing sstatements sabout sbioavailability sis strue?
A. Bioavailability sissues sare sespecially simportant sfor sdrugs swith snarrow
stherapeutic sranges sor ssustained srelease smechanisms.
B. All sbrands sof sa sdrug shave sthe ssame sbioavailability.
C. Drugs sthat sare sadministered smore sthan sonce sa sday shave sgreater sbioavailability
sthan sdrugs sgiven sonce sdaily.
D. Combining san sactive sdrug swith san sinert ssubstance sdoes snot saffect sbioavailability.
ANS: s A PTS: s 1
16. Which sof sthe sfollowing sstatements sabout sthe smajor sdistribution sbarriers s(blood-
brain sor sfetal-placental) sis strue?
A. Water ssoluble sand sionized sdrugs scross sthese sbarriers srapidly.
B. The sblood-brain sbarrier sslows sthe sentry sof smany sdrugs sinto sand sfrom sbrain scells.
C. The sfetal-placental sbarrier sprotects sthe sfetus sfrom sdrugs staken sby sthe smother.
D. Lipid ssoluble sdrugs sdo snot spass sthese sbarriers sand sare ssafe sfor spregnant swomen.
ANS: s B PTS: s 1
17. Drugs sare smetabolized smainly sby sthe sliver svia sPhase sI sor sPhase sII sreactions. sThe
spurpose sof sboth sof sthese stypes sof sreactions sis sto:
A. Inactivate sprodrugs sbefore sthey scan sbe sactivated sby starget stissues
B. Change sthe sdrugs sso sthey scan scross splasma smembranes
C. Change sdrug smolecules sto sa sform sthat san sexcretory sorgan scan sexcrete
D. Make sthese sdrugs smore sionized sand spolar sto sfacilitate sexcretion
ANS: s C PTS: s 1
18. Once sthey shave sbeen smetabolized sby sthe sliver, sthe smetabolites smay sbe:
A. More sactive sthan sthe sparent sdrug
B. Less sactive sthan sthe sparent sdrug
C. Totally s“deactivated” sso sthat sthey sare sexcreted swithout sany seffect
D. All sof sthe sabove
ANS: s D PTS: s 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
19. All sdrugs scontinue sto sact sin sthe sbody suntil sthey sare schanged sor sexcreted. sThe sability
sof sthe sbody sto sexcrete sdrugs svia sthe srenal ssystem swould sbe sincreased sby:
A. Reduced scirculation sand sperfusion sof sthe skidney
B. Chronic srenal sdisease
C. Competition sfor sa stransport ssite sby sanother sdrug
D. Unbinding sa snonvolatile sdrug sfrom splasma sproteins
ANS: s D PTS: s 1
20. Steady sstate sis:
A. The spoint son sthe sdrug sconcentration scurve swhen sabsorption sexceeds sexcretion
B. When sthe samount sof sdrug sin sthe sbody sremains sconstant
C. When sthe samount sof sdrug sin sthe sbody sstays sbelow sthe sMTC
D. All sof sthe sabove
ANS: s B PTS: s 1
21. Two sdifferent spain smeds sare sgiven stogether sfor spain srelief. sThe sdrug-drug sinteraction sis:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
ANS: s D PTS: s 1
22. Actions staken sto sreduce sdrug-drug sinteraction sproblems sinclude sall sof sthe
sfollowing sEXCEPT:
A. Reducing sthe sdose sof sone sof sthe sdrugs
B. Scheduling stheir sadministration sat sdifferent stimes
C. Prescribing sa sthird sdrug sto scounteract sthe sadverse sreaction sof sthe scombination
D. Reducing sthe sdosage sof sboth sdrugs
ANS: s C PTS: s 1
23. Phase sI soxidative-reductive sprocesses sof sdrug smetabolism srequire scertain snutritional
selements. sWhich sof sthe sfollowing swould sreduce sor sinhibit sthis sprocess?
A. Protein smalnutrition
B. Iron sdeficiency sanemia
C. Both sA sand sB
D. Neither sA snor sB
ANS: s D PTS: s 1
24. The stime srequired sfor sthe samount sof sdrug sin sthe sbody sto sdecrease sby s50% sis scalled:
A. Steady sstate
B. Half-life
C. Phase sII smetabolism
D. Reduced sbioavailability stime
ANS: s B PTS: s 1
LPharmacotherapeutics for Advanced Practice
A Practical Approach
Virginia Poole Arcangelo, Andrew M. Peterson, Veronica Wilbur,Tep M. Kang
5th Edition
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
Table of content
Chapter I Issues for the Practitioner in Drug Therapy
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
Chapter 5 Pharmacotherapy Principles in Older Adults
Chapter 6 Principles of Antimicrobial Therapy
Chapter 7 Pharmacogenomies
Chapter 8 The Economics of Pharmacotherapeutics
Chapter 9 Pharmacotherapy of Pain Management
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
Chapter 11 Cannabis and Pain Management
Chapter 12 Contact Dermatitis
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin
Chapter 14 Psoriasis
Chapter I5 Acne Vulgaris and Rosacea
Chapter 16 Ophthalmic Disorders
Chapter I7 Otitis Media and Otitis Externa
Chapter I8 Hypertension
Chapter I9 Hyperlipidemia
Chapter 20 Chronic Stable Angina and Myocardial Infarction
Chapter 2I Heart Failure
Chapter 22 Arrhythmias
Chapter 23 Respiratory Infections
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
Chapter 25 Gastric, Functional, and Inflammatory Bowel Disorders
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
Chapter 27 Liver Diseases
Chapter 28 Urinary Tract Infection
Chapter 29 Prostatic Disorders and Erectile Dysfunction
Chapter 30 Overactive Bladder
Chapter 3I Sexually Transmitted Infections
Chapter 32 Osteoarthritis and Gout
Chapter 33 Osteoporosis
Chapter 34 Rheumatoid Arthritis
Chapter 35 Headaches
Chapter 36 Seizure Disorders
Chapter 37 Alzheimer's Disease
Chapter 38 Parkinson's Disease
Chapter 39 Major Depressive Disorder and Bipolar Disorders
Chapter 40 Anxiety Disorders
Chapter 41 Sleep Disorders
Chapter 42 Attention Deficit Hyperactivity Disorder
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
Chapter 43 Substance Use Disorders
Chapter 44 Diabetes Mellitus
Chapter 45 Thyroid and Parathyroid Disorders
Chapter 46 Allergies and Allergic Reactions
Chapter 47 Human Immunodeficiency Virus
Chapter 48 Organ Transplantation
Chapter 49 Thromboembolic Disorders
Chapter 50 Anemias
Chapter 5l Immunizations
Chapter 52 Smoking Cessation
Chapter 53 Weight Loss
Chapter 54 Contraception
Chapter 55 Menopause
Chapter 56 Vaginitis
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007614
lOM oA R c PS D| 21 007614
Chapter 1 Issues for the Practitioner in Drug Therapy
MULTIPLE CHOICE
1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
ANS: C PTS: 1
2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
ANS: D PTS: 1
3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1
4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
ANS: B PTS: 1
5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
ANS: A PTS: 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
MULTIPLE CHOICE
1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
ANS: A PTS: 1
2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
ANS: C PTS: 1
3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
ANS: B PTS: 1
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
ANS: C PTS: 1
5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
ANS: B PTS: 1
6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
lOM oA R c PS D| 21 007614
D. Is directly related to the drug circulating to the target tissues
ANS: A PTS: 1
7. The spoint sin stime son sthe sdrug sconcentration scurve sthat sindicates sthe sfirst ssign sof sa
stherapeutic seffect sis sthe:
A. Minimum sadverse seffect slevel
B. Peak sof saction
C. Onset sof saction
D. Therapeutic srange
ANS: s C PTS: s 1
8. Phenytoin srequires sa strough slevel sbe sdrawn. sPeak sand strough slevels sare sdone:
A. When sthe sdrug shas sa swide stherapeutic srange
B. When sthe sdrug swill sbe sadministered sfor sa sshort stime sonly
C. When sthere sis sa shigh scorrelation sbetween sthe sdose sand ssaturation sof sreceptor ssites
D. To sdetermine sif sa sdrug sis sin sthe stherapeutic srange
ANS: s D PTS: s 1
9. A slaboratory sresult sindicates sthe speak slevel sfor sa sdrug sis sabove sthe sminimum
stoxic sconcentration. sThis smeans sthat sthe:
A. Concentration swill sproduce stherapeutic seffects
B. Concentration swill sproduce san sadverse sresponse
C. Time sbetween sdoses smust sbe sshortened
D. Duration sof saction sof sthe sdrug sis stoo slong
ANS: s B PTS: s 1
10. Drugs sthat sare sreceptor sagonists smay sdemonstrate swhat sproperty?
A. Irreversible sbinding sto sthe sdrug sreceptor ssite
B. Up-regulation swith schronic suse
C. Desensitization sor sdown-regulation swith scontinuous suse
D. Inverse srelationship sbetween sdrug sconcentration sand sdrug saction
ANS: s C PTS: s 1
11. Drugs sthat sare sreceptor santagonists, ssuch sas sbeta sblockers, smay scause:
A. Down-regulation sof sthe sdrug sreceptor
B. An sexaggerated sresponse sif sabruptly sdiscontinued
C. Partial sblockade sof sthe seffects sof sagonist sdrugs
D. An sexaggerated sresponse sto scompetitive sdrug sagonists
ANS: s B PTS: s 1
12. Factors sthat saffect sgastric sdrug sabsorption sinclude:
A. Liver senzyme sactivity
B. Protein-binding sproperties sof sthe sdrug smolecule
C. Lipid ssolubility sof sthe sdrug
D. Ability sto schew sand sswallow
ANS: s C PTS: s 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
13. Drugs sadministered svia sintravenous s(IV) sroute:
A. Need sto sbe slipid ssoluble sin sorder sto sbe seasily sabsorbed
B. Begin sdistribution sinto sthe sbody simmediately
C. Are seasily sabsorbed sif sthey sare snonionized
D. May suse spinocytosis sto sbe sabsorbed
ANS: s B PTS: s 1
14. When sa smedication sis sadded sto sa sregimen sfor sa ssynergistic seffect, sthe scombined seffect
sof sthe sdrugs sis:
A. The ssum sof sthe seffects sof seach sdrug sindividually
B. Greater sthan sthe ssum sof sthe seffects sof seach sdrug sindividually
C. Less sthan sthe seffect sof seach sdrug sindividually
D. Not spredictable, sas sit svaries swith seach sindividual
ANS: s B PTS: s 1
15. Which sof sthe sfollowing sstatements sabout sbioavailability sis strue?
A. Bioavailability sissues sare sespecially simportant sfor sdrugs swith snarrow
stherapeutic sranges sor ssustained srelease smechanisms.
B. All sbrands sof sa sdrug shave sthe ssame sbioavailability.
C. Drugs sthat sare sadministered smore sthan sonce sa sday shave sgreater sbioavailability
sthan sdrugs sgiven sonce sdaily.
D. Combining san sactive sdrug swith san sinert ssubstance sdoes snot saffect sbioavailability.
ANS: s A PTS: s 1
16. Which sof sthe sfollowing sstatements sabout sthe smajor sdistribution sbarriers s(blood-
brain sor sfetal-placental) sis strue?
A. Water ssoluble sand sionized sdrugs scross sthese sbarriers srapidly.
B. The sblood-brain sbarrier sslows sthe sentry sof smany sdrugs sinto sand sfrom sbrain scells.
C. The sfetal-placental sbarrier sprotects sthe sfetus sfrom sdrugs staken sby sthe smother.
D. Lipid ssoluble sdrugs sdo snot spass sthese sbarriers sand sare ssafe sfor spregnant swomen.
ANS: s B PTS: s 1
17. Drugs sare smetabolized smainly sby sthe sliver svia sPhase sI sor sPhase sII sreactions. sThe
spurpose sof sboth sof sthese stypes sof sreactions sis sto:
A. Inactivate sprodrugs sbefore sthey scan sbe sactivated sby starget stissues
B. Change sthe sdrugs sso sthey scan scross splasma smembranes
C. Change sdrug smolecules sto sa sform sthat san sexcretory sorgan scan sexcrete
D. Make sthese sdrugs smore sionized sand spolar sto sfacilitate sexcretion
ANS: s C PTS: s 1
18. Once sthey shave sbeen smetabolized sby sthe sliver, sthe smetabolites smay sbe:
A. More sactive sthan sthe sparent sdrug
B. Less sactive sthan sthe sparent sdrug
C. Totally s“deactivated” sso sthat sthey sare sexcreted swithout sany seffect
D. All sof sthe sabove
ANS: s D PTS: s 1
, Test Bank - Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition (Arcangelo, 2022)
19. All sdrugs scontinue sto sact sin sthe sbody suntil sthey sare schanged sor sexcreted. sThe sability
sof sthe sbody sto sexcrete sdrugs svia sthe srenal ssystem swould sbe sincreased sby:
A. Reduced scirculation sand sperfusion sof sthe skidney
B. Chronic srenal sdisease
C. Competition sfor sa stransport ssite sby sanother sdrug
D. Unbinding sa snonvolatile sdrug sfrom splasma sproteins
ANS: s D PTS: s 1
20. Steady sstate sis:
A. The spoint son sthe sdrug sconcentration scurve swhen sabsorption sexceeds sexcretion
B. When sthe samount sof sdrug sin sthe sbody sremains sconstant
C. When sthe samount sof sdrug sin sthe sbody sstays sbelow sthe sMTC
D. All sof sthe sabove
ANS: s B PTS: s 1
21. Two sdifferent spain smeds sare sgiven stogether sfor spain srelief. sThe sdrug-drug sinteraction sis:
A. Synergistic
B. Antagonistic
C. Potentiative
D. Additive
ANS: s D PTS: s 1
22. Actions staken sto sreduce sdrug-drug sinteraction sproblems sinclude sall sof sthe
sfollowing sEXCEPT:
A. Reducing sthe sdose sof sone sof sthe sdrugs
B. Scheduling stheir sadministration sat sdifferent stimes
C. Prescribing sa sthird sdrug sto scounteract sthe sadverse sreaction sof sthe scombination
D. Reducing sthe sdosage sof sboth sdrugs
ANS: s C PTS: s 1
23. Phase sI soxidative-reductive sprocesses sof sdrug smetabolism srequire scertain snutritional
selements. sWhich sof sthe sfollowing swould sreduce sor sinhibit sthis sprocess?
A. Protein smalnutrition
B. Iron sdeficiency sanemia
C. Both sA sand sB
D. Neither sA snor sB
ANS: s D PTS: s 1
24. The stime srequired sfor sthe samount sof sdrug sin sthe sbody sto sdecrease sby s50% sis scalled:
A. Steady sstate
B. Half-life
C. Phase sII smetabolism
D. Reduced sbioavailability stime
ANS: s B PTS: s 1
